Patents by Inventor Stephanie Erbar

Stephanie Erbar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220362388
    Abstract: The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.
    Type: Application
    Filed: July 1, 2020
    Publication date: November 17, 2022
    Inventors: Heinrich HAAS, Jorge MORENO HERRERO, Anne Marion Genevieve SCHLEGEL, Stephanie ERBAR
  • Publication number: 20220313811
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
    Type: Application
    Filed: April 11, 2022
    Publication date: October 6, 2022
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero
  • Patent number: 11318195
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 3, 2022
    Assignees: BIONTECH SE, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero
  • Publication number: 20210023100
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.
    Type: Application
    Filed: January 10, 2019
    Publication date: January 28, 2021
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Jorge Herrero Moreno, Thorsten Klamp, Sebastian Kreiter, Mustafa Diken
  • Publication number: 20190321458
    Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.
    Type: Application
    Filed: July 14, 2017
    Publication date: October 24, 2019
    Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Reuter, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero